Patient characteristics according to transplantation
. | Autologous transplantation . | Allogeneic transplantation . | All patients . |
|---|---|---|---|
| Total cases, no. | 137 | 25 | 162 |
| Protocol, no. | |||
| 89-064 | 32 | 12 | 44 |
| 94-055 | 105 | 13 | 118 |
| Median age, y (range) | 51 (19-66) | 47 (28-55) | 49 (19-66) |
| Sex, no. (%) | |||
| Male | 101 (74) | 20 (80) | 121 (75) |
| Female | 36 (26) | 5 (20) | 41 (25) |
| Median time from diagnosis to transplantation, mo (range) | 46 (7-212) | 45 (11-145) | 46 (7-212) |
| Prior therapy, no. (%) | |||
| Alkylator only | 8 (6) | 2 (8) | 10 (6) |
| Fludarabine only | 29 (22) | 8 (32) | 37 (23) |
| Sequential alkylator and fludarabine | 59 (43) | 11 (44) | 70 (43) |
| Concomitant alkylator and fludarabine with or without rituximab | 41 (30) | 4 (16) | 45 (27) |
| IgH mutational status, no. (%) | |||
| Mutated, at least 2 | 11 (8) | 4 (16) | 15 (9) |
| Unmutated, less than 2% | 124 (90) | 21 (80) | 145 (90) |
| Unknown | 2 (1) | 0 | 2 (1) |
. | Autologous transplantation . | Allogeneic transplantation . | All patients . |
|---|---|---|---|
| Total cases, no. | 137 | 25 | 162 |
| Protocol, no. | |||
| 89-064 | 32 | 12 | 44 |
| 94-055 | 105 | 13 | 118 |
| Median age, y (range) | 51 (19-66) | 47 (28-55) | 49 (19-66) |
| Sex, no. (%) | |||
| Male | 101 (74) | 20 (80) | 121 (75) |
| Female | 36 (26) | 5 (20) | 41 (25) |
| Median time from diagnosis to transplantation, mo (range) | 46 (7-212) | 45 (11-145) | 46 (7-212) |
| Prior therapy, no. (%) | |||
| Alkylator only | 8 (6) | 2 (8) | 10 (6) |
| Fludarabine only | 29 (22) | 8 (32) | 37 (23) |
| Sequential alkylator and fludarabine | 59 (43) | 11 (44) | 70 (43) |
| Concomitant alkylator and fludarabine with or without rituximab | 41 (30) | 4 (16) | 45 (27) |
| IgH mutational status, no. (%) | |||
| Mutated, at least 2 | 11 (8) | 4 (16) | 15 (9) |
| Unmutated, less than 2% | 124 (90) | 21 (80) | 145 (90) |
| Unknown | 2 (1) | 0 | 2 (1) |